Ki‑67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively

  • Authors:
    • Marcelo Campos
    • Silvana Gisele Pegorin De Campos
    • Guilherme Gomes Ribeiro
    • Flávia Coltri Eguchi
    • Sandra Regina Morini Da Silva
    • Cleyton Zanardo De Oliveira
    • Allini Mafra Da Costa
    • Emílio Carlos Curcelli
    • Marcos Ceita Nunes
    • Valter Penna
    • Adhemar Longatto‑Filho
  • View Affiliations

  • Published online on: March 5, 2013     https://doi.org/10.3892/ol.2013.1226
  • Pages: 1527-1535
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Soft tissue sarcomas (STSs) are a heterogeneous group of mesenchymal tumors of >50 subtypes. However, STSs represent <1% of types of cancer. Despite this low frequency, the disease is aggressive and treatment, when possible, is based on traditional chemotherapies. A number of cases of resistance to adjuvant therapies have been reported. Metastases are commonly identified in STS patients during diagnosis and the development of effective clinical parameters is crucial for correct management of the disease. The use of biological markers in cancer is a useful tool to determine patient prognosis. Ki‑67 is a protein marker for proliferation of somatic cells and is widely used in prognostic studies of various types of tumor, including STSs. Cluster of differentiation 100 (CD100) is a member of the semaphorin family. The family was initially described as axon guidance molecules important for angiogenesis, organogenesis, apoptosis and neoplasia. CD100 was previously utilized as a prognostic factor in tumors and also in STSs. In the present study, protein expression of Ki‑67 and CD100 was analyzed by immunohistochemistry in samples of STS patients of the Barretos Cancer Hospital (Barretos, Brazil) to establish prognostic criteria of the disease. Results demonstrate a correlation between CD100 expression and poor prognosis, consistent with a previous study. Moreover, the expression of Ki‑67 was identified to correlate with presence of local or locoregional recurrence. To the best of our knowledge, no large casuistic study has revealed this correlation between Ki‑67 and local recurrence in STSs. The use of Ki‑67 and CD100 as markers in clinical pathological analysis may be suitable as a prognostic criterion in disease progression.
View Figures
View References

Related Articles

Journal Cover

May 2013
Volume 5 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Campos M, Pegorin De Campos SG, Ribeiro GG, Eguchi FC, Morini Da Silva SR, De Oliveira CZ, Da Costa AM, Curcelli EC, Nunes MC, Penna V, Penna V, et al: Ki‑67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively. Oncol Lett 5: 1527-1535, 2013
APA
Campos, M., Pegorin De Campos, S.G., Ribeiro, G.G., Eguchi, F.C., Morini Da Silva, S.R., De Oliveira, C.Z. ... Longatto‑Filho, A. (2013). Ki‑67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively. Oncology Letters, 5, 1527-1535. https://doi.org/10.3892/ol.2013.1226
MLA
Campos, M., Pegorin De Campos, S. G., Ribeiro, G. G., Eguchi, F. C., Morini Da Silva, S. R., De Oliveira, C. Z., Da Costa, A. M., Curcelli, E. C., Nunes, M. C., Penna, V., Longatto‑Filho, A."Ki‑67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively". Oncology Letters 5.5 (2013): 1527-1535.
Chicago
Campos, M., Pegorin De Campos, S. G., Ribeiro, G. G., Eguchi, F. C., Morini Da Silva, S. R., De Oliveira, C. Z., Da Costa, A. M., Curcelli, E. C., Nunes, M. C., Penna, V., Longatto‑Filho, A."Ki‑67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively". Oncology Letters 5, no. 5 (2013): 1527-1535. https://doi.org/10.3892/ol.2013.1226